BRACAnalysis
Hereditary Breast and Ovarian Cancer Risk
ApprovedCommercial
Key Facts
Indication
Hereditary Breast and Ovarian Cancer Risk
Phase
Approved
Status
Commercial
Company
About Myriad Genetics
Myriad Genetics is a pioneer in genetic testing, having discovered the BRCA1/2 genes and launched the first commercial hereditary cancer risk test. With over 30 years of experience, the company now performs over 1 million genetic tests annually and serves more than 51,000 active ordering physicians. Myriad's mission is to advance health and well-being for all by providing clear, actionable genetic insights that empower personalized healthcare decisions.
View full company profile